

10-1-2017

Fasting ghrelin levels are decreased in obese subjects and are significantly related with insulin resistance and body mass index

Dimitrios Papandreou
Zayed University

Christos Karavolias
The Doctors Medical Center

Fotini Arvaniti
Second Medical Unit

Eleana Kafeza
Zayed University

Fatima Sidawi
Zayed University

Follow this and additional works at: <https://zuscholars.zu.ac.ae/works>



Part of the [Business Commons](#)

Recommended Citation

Papandreou, Dimitrios; Karavolias, Christos; Arvaniti, Fotini; Kafeza, Eleana; and Sidawi, Fatima, "Fasting ghrelin levels are decreased in obese subjects and are significantly related with insulin resistance and body mass index" (2017). *All Works*. 1658.

<https://zuscholars.zu.ac.ae/works/1658>

This Article is brought to you for free and open access by ZU Scholars. It has been accepted for inclusion in All Works by an authorized administrator of ZU Scholars. For more information, please contact Yrjo.Lappalainen@zu.ac.ae, nikesh.narayanan@zu.ac.ae.

Fasting Ghrelin Levels Are Decreased in Obese Subjects and Are Significantly Related With Insulin Resistance and Body Mass Index

Dimitrios Papandreou^{1*}, Christos Karavolias², Fotini Arvaniti³, Eleana Kafeza⁴, Fatima Sidawi¹

¹Department of Health Sciences, CNHS, Zayed University, Abu Dhabi, United Arab Emirates; ²The Doctors Medical Center, Abu Dhabi, United Arab Emirates; ³Medical Unit, Hellenic House of Parliament, Athens, Greece; ⁴College of Technological Innovation, Zayed University, Abu Dhabi, United Arab Emirates

Abstract

Citation: Papandreou D, Karavolias C, Arvaniti F, Kafeza E, Sidawi F. Fasting Ghrelin Levels Are Decreased in Obese Subjects and Are Significantly Related With Insulin Resistance and Body Mass Index. Open Access Maced J Med Sci. 2017 Oct 15; 5(6):699-702. <https://doi.org/10.3889/oamjms.2017.182>

Keywords: Ghrelin; obesity; Insulin resistance; glucose; Body mass Index.

***Correspondence:** Dimitrios Papandreou, Department of Health Sciences, CNHS, Zayed University, Abu Dhabi, United Arab Emirates. E-mail: dimitrios.papandreou@zu.ac.ae

Received: 07-Jul-2017; **Revised:** 20-Jul-2017; **Accepted:** 19-Aug-2017; **Online first:** 14-Oct-2017

Copyright: © 2017 Dimitrios Papandreou, Christos Karavolias, Fotini Arvaniti, Eleana Kafeza, Fatima Sidawi. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Funding: This research did not receive any financial support.

Competing Interests: The authors have declared that no competing interests exist.

BACKGROUND: Ghrelin is a 28-amino acid peptide that predominantly produced by the stomach. Strong evidence indicates the effects of ghrelin in the regulation of metabolic functions and its potential role in the aetiology of obesity.

AIM: The aim of this study was to investigate the relationship of ghrelin levels with obesity, insulin resistance and glucose in normal and obese subjects.

METHODS: Thirteen normal (n = 13) and seven (n = 7) obese weight subjects aged 20-22 participated in the study. Fasting plasma ghrelin, insulin and glucose levels were measured after overnight fasting. HOMA-IR was calculated to evaluate insulin resistance.

RESULTS: Ghrelin and insulin levels were found to be statistically significantly lower and higher in obese subjects (P < 0.001), respectively. Glucose levels were clinically higher in obese subjects but not statistically significant. Fasting plasma ghrelin was negatively correlated with BMI (r = -0.77, P < 0.001), fasting insulin levels (r = -0.55, P < 0.001) and HOMA-IR (r = -0.66, P < 0.001). There was no correlation between ghrelin and glucose. In multiple regression analysis, insulin levels (Beta: -2.66, 95% CI: -2.49, -2.78, P < 0.001) HOMA-IR (Beta: -2.41, 95% CI: -2.33, -2.55, P < 0.001) and BMI (Beta: -1.77, 95% CI: -1.66, -1.89, P < 0.001) were significant independent determinants of fasting ghrelin.

CONCLUSION: Obese subjects have low fasting ghrelin levels that they are significantly related to insulin resistance and body mass index. More prospective studies are needed to establish the role of ghrelin in the pathogenesis of human obesity.

Introduction

Ghrelin is a 28-amino acid that is produced in the stomach. Other organs such as liver heart and pancreas can also produce ghrelin but in lower levels [1]. Strong evidence indicates the effects of ghrelin in its potential role in the pathogenesis of obesity, insulin resistance (IR) and types 2 diabetes [2].

More recently, research on ghrelin has improved our understanding of the mechanisms involve food intake, fat accumulation, and the development of other metabolic disturbances [3].

The role of ghrelin in the regulation of glucose was initially hypothesized after an observation of a negative correlation of insulin and ghrelin [4].

One year later Schofl et al. [5] supported the involvement of ghrelin in the development of IR and typed two diabetes. Total ghrelin levels have also been found to be negatively correlated with IR in children and adolescents [6].

Food intake is the most important factor that influences ghrelin levels. Usually, total ghrelin levels are rising during the night and decrease after breakfast [7]. A long-term high fat diet has found to reduce plasma total ghrelin levels and stomach content [8]. Also, many studies have reported that ghrelin levels are negatively associated with body mass index (BMI) [9, 10].

We hypothesized that obese individuals would present with elevated fasting ghrelin levels and there is no relationship between ghrelin and insulin levels.

Methods

Twenty healthy subjects (13 with normal weight and seven obese) participated in the study aged 20-22 years old. A detailed medical history was taken by the clinic's doctor. Subjects with a medical history of liver, renal, or heart or taking any medications and supplements were excluded from the study. The study received approval from the ethical committees of "Zayed University" and "Doctors Medical Center" while all subjects signed a consent form.

Body weight and height were collected for all subjects using SECA 600 model while obesity was defined as BMI > 30 kg/m², according to the criteria of International Obesity Task Force [11].

Plasma ghrelin, glucose, insulin and C-reactive protein (CRP) levels were measured in the morning after fasting overnight. Blood samples were drawn by a certified nurse by venipuncture into 10-ml empty evacuated placed on ice tubes. The tubes were immediately centrifuged at 2000 x g for 10 min. Plasma ghrelin levels were measured with the immunochemiluminometric assay (IDS, SMBH, Germany) with an inter-assay coefficient of 6.2%. Plasma glucose levels were measured using a hexokinase enzymatic reference method (Cobas, Roche USA). Fasting insulin levels were measured using ECLIA method (Cobas 6000, Roche, USA) while CRP was measured with Immunoturbidimetry (Cobas 6000, Roche, USA). HOMA-IR was used to evaluate insulin resistance (fasting serum insulin (pmol/l) × fasting plasma glucose (mmol l⁻¹)/22.5) [12].

Statistical Analysis

Fasting levels of ghrelin, glucose and insulin were compared by a *t*-test between normal and obese groups. Pearson's correlations were calculated between anthropometric and biochemical variables and ghrelin levels. Moreover, the effect of several variables on ghrelin concentrations was considered with multiple linear regression analysis. In the regression model, we verified ghrelin as a dependent variable and included weight, BMI, glucose, Insulin, glucose and HOMA-IR as independent variables. Values with *P* < 0.05 were considered statistically significant.

Results

Fasting plasma levels were significantly lower in an obese subject compared to normal ones (Table 1, Figure 1). Also, BMI, plasma insulin and HOMA-IR

were significantly higher in the obese group (Table 1).

Table 1: Baseline characteristics of Normal and Obese subjects

	Normal (n = 13)	OB (n = 7)	p-value
Age, y	21±0.8	21±2.07	0.298
Height, cm	159±8.2	161±3.7	0.183
Weight, Kg	53±8.7	79±11	0.001*
BMI, kg/m ²	20.6±3	31.3±2.1	0.001*
CRP	1.2±1.1	2.0±1.0	0.065
Glucose, mmol/l	5.1±6.5	5.5±6.7	0.072
Insulin, pmol/l	8.2±2.7	14.5±2.3	0.041*
HOMA-IR	1.85±0.5	3.54±0.8	0.004*
Ghrelin, pg/ml	541±202	440±140	0.002*

Data is presented as mean ± SD; **P* < 0.05 = Statistically significant difference.

Fasting plasma ghrelin was negatively correlated with BMI (*r* = -0.77, *P* < 0.001), fasting insulin levels (*r* = -0.55, *P* < 0.001) and HOMA-IR (*r* = -0.66, *P* < 0.001). There was no correlation between ghrelin and glucose (Table 2).




Figure 1: Ghrelin levels of obese subjects were statistically significant compare to normal ones (*P* < 0.005)

In multiple regression analysis, insulin levels (Beta: -2.66, 95% CI: -2.49, -2.78, *P* < 0.001) HOMA-IR (Beta: -2.41, 95% CI: -2.33, -2.55, *P* < 0.001) and BMI (Beta: -1.77, 95% CI: -1.66, -1.89, *P* < 0.001) were significant independent determinants of fasting ghrelin (Table 3).

Table 2: Pearson's Correlation between Ghrelin and other variables

	r	p-value
Age	0.51	0.332
Height	-0.34	0.566
Weight	-0.78	0.002*
BMI	-0.77	0.001*
Glucose	-0.51	0.455
Insulin	-0.55	0.001*
HOMA-IR	-0.66	0.001*

**P* < 0.05: Statistically significant.

Discussion

In our study contrary to our hypothesis, obese subjects have lower concentrations of ghrelin and

higher insulin levels than the age-matched lean control subjects. This is an indication that ghrelin is downregulated in human obesity. This result may be because of elevated insulin levels since ghrelin levels were independently associated with insulin and HOMA-IR. These findings are in agreement with other research studies [13, 14]. Ghrelin was shown to inhibit insulin secretion from pancreatic islets in rodents [15].

Table 3: Multiple regression analysis of Ghrelin with anthropometric and biochemical variables

Variable	Beta	95% CI	P
Weight	-0.44	-0.32, -0.55	0.505
BMI	-1.77	-1.66, -1.89	0.001*
Glucose	-0.32	-0.37, -0.49	0.668
Insulin	-2.66	-2.49, -2.78	0.001*
HOMA-IR	-2.41	-2.33, -2.55	0.001*

*p < 0.05: Statistically significant.

Ghrelin secretion may be affected by adiposity through insulin and glucose metabolism [16]. Studies performed in humans demonstrated that i.v. Administration of insulin induces a fall in ghrelin levels [17]. Thus, reduced ghrelin levels in obesity may be the consequence of increased insulin levels in these subjects.

In our study, ghrelin levels were negatively correlated with body weight and independently associated with BMI. Research evidence shows that plasma ghrelin levels are negatively correlated with body mass index and body fat percentage [18]. Also, reduced ghrelin secretion in obese patients was found to be an adaptive mechanism to a long-term positive energy balance [19].

The present study has some limitations that should be addressed. The small sample of the study has an important influence on the results. Also, we did not take in consideration any dietary habits, genetic information and socioeconomic factors that could also play an important role in obesity. Moreover, this was a one-time measure and may not represent the reality of the indices. Nevertheless, the results will provide some evidence of the relation of fasting ghrelin levels with insulin resistance and give some light on the pathogenesis of human obesity.

In conclusion, Ghrelin is deregulated in obesity and associated with insulin and insulin resistance and thus may be considered a suitable target for the management of insulin resistance. More studies are needed to elucidate the effects of ghrelin in the pathogenesis of human obesity.

Acknowledgment

We would like to thank the nurses in the Doctor's Medical Center for their patient and support.

Authors' Contributions

DP contributed to the conception and design of the study, interpretation of data writing of the manuscript and final approval of the version to be published. CK contributed to the design of the study, interpretation of the results writing a part of the manuscript and final approval of the paper. FA contributed to the collection of data, draft a part of the manuscript and final approval of the paper to be published. EK contributed to the collection and analysis of data, draft a part of the manuscript and final approval of the paper. FS contributed in the data collection, draft a part of the manuscript and final approval of the manuscript to be published.

References

- Ghelardoni S, Carnicelli V, Frascarelli S, et al. Ghrelin tissue distribution: comparison between gene and protein expression. *J Endocrinol Invest.* 2006; 29:115–121. <https://doi.org/10.1007/BF03344083> PMID:16610236
- Ukkola O. Ghrelin in Type 2 diabetes mellitus and metabolic syndrome. *Mol Cell Endocrinol.* 2011; 340:26–28. <https://doi.org/10.1016/j.mce.2011.02.009> PMID:21419192
- Boguszewski CL, Paz-Filho G, Velloso LA. Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain. *Endokrynol Pol.* 2010; 61:194–206. PMID:20464707
- Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. *Diabetes.* 2001; 50:707–709. <https://doi.org/10.2337/diabetes.50.4.707> PMID:11289032
- Schöfl C, Horn R, Schill T, et al. Circulating ghrelin levels in patients with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2002; 87:4607–4610. <https://doi.org/10.1210/jc.2002-020505> PMID:12364442
- Ikezaki A, Hosoda H, Ito K, et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. *Diabetes.* 2002; 51:3408–3411. <https://doi.org/10.2337/diabetes.51.12.3408> PMID:12453893
- Marzullo P, Caumo A, Savia G, et al. Predictors of postabsorptive ghrelin secretion after intake of different macronutrients. *J Clin Endocrinol Metab.* 2006; 91: 4124–4130. <https://doi.org/10.1210/jc.2006-0270> PMID:16882748
- Moesgaard SG, Ahren B, Carr R, et al. Effects of high-fat feeding and fasting on ghrelin expression in the mouse stomach. *Regul Pept.* 2004; 120: 261–267. <https://doi.org/10.1016/j.regpep.2004.03.018> PMID:15177945
- Greenman Y, Golani N, Gilad S, et al. Ghrelin secretion is modulated in a nutrient- and gender-specific manner. *Clin Endocrinol.* 2004; 60: 382–388. <https://doi.org/10.1111/j.1365-2265.2004.01993.x>
- Purnell JQ, Weigle DS, Breen P, et al. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. *J Clin Endocrinol Metab.* 2003; 88: 5747–5752. <https://doi.org/10.1210/jc.2003-030513> PMID:14671163
- Cole TJ, Bellizzi CM, Flegal MK, et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ.* 2000; 320: 1240–1243. <https://doi.org/10.1136/bmj.320.7244.1240> PMID:10797032 PMID:PMC27365
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis

- model assessment: IR and beta-cell function from fasting plasma glucose and insulin concentration in man. *Diabetologia*. 1985; 28: 412-419. <https://doi.org/10.1007/BF00280883> PMID:3899825
13. Lucidi P, Murdolo G, Di Loreto C, et al. Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia. *Diabetes*. 2002; 51: 2911–2914. <https://doi.org/10.2337/diabetes.51.10.2911> PMID:12351426
14. Flanagan DE, Evans ML, Monsod TP, et al. The influence of insulin on circulating ghrelin. *American Journal of Physiology, Endocrinology and Metabolism*. 2003; 284: E313–E316. <https://doi.org/10.1152/ajpendo.00569.2001> PMID:12531744
15. Qader SS, Lundquist I, Ekelund M, et al. Ghrelin activates neuronal constitutive nitric oxide synthase in pancreatic islet cells while inhibiting insulin release and stimulating glucagon release. *Regul Pept*. 2005; 128: 51–56. <https://doi.org/10.1016/j.regpep.2004.12.018> PMID:15721487
16. Soriano-Guillén L, Barrios V, Martos G, et al. Effect of oral glucose administration on ghrelin levels in obese children. *Eur J Endocrinol*. 2004; 151: 119–121. <https://doi.org/10.1530/eje.0.1510119> PMID:15248831
17. Anderwald C, Brabant G, Bernroider E, et al. Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients. *Diabetes*. 2003; 52: 1792–1798. <https://doi.org/10.2337/diabetes.52.7.1792> PMID:12829648
18. Covasa M, Swartz T. The role of ghrelin in eating behaviour. In: Preedy VR, Watson RR, Martin CR (eds), *Handbook of behavior, food and nutrition*. Springer Science, New York, 2011; 175-188. https://doi.org/10.1007/978-0-387-92271-3_13
19. Sato T, Ida T, Nakamura Y, et al. Physiological roles of ghrelin on obesity. *Obes Res Clin Pract*. 2014; 8: e405-413. <https://doi.org/10.1016/j.orcp.2013.10.002> PMID:25263830